Summary
Sublingual administration of nifedipine 10 mg to 11 patients and 20 mg to 6 patients with arterial hypertension caused a rapid and significant decrease in blood pressure in both groups. The average maximal reductions in the two groups were 21/16 mm Hg and 27/21 mm Hg. A concomitant rise in heart rate was found. Forearm blood flow showed a significant increase and the calculated vascular resistance a significant decrease 15–60 min after administration of both the 10 mg and the 20 mg doses. There was a negative correlation between basal vascular resistance and the maximal change of this parameter (r=−0.72, p<0.01). Plasma concentrations of nifedipine showed considerable individual variation, with slow absorption in some patients, which indicated failure of sublingual absorption in them. The difference between the mean plasma concentration in the two dose groups was statistically significant after 45 min. A negative correlation was present between the plasma concentration of nifedipine and the observed change in calculated vascular resistance (r=−0.74 at t=30 min). Treatment of 10 hypertensive patients with nifedipine 30–60 mg daily for 6 weeks reduced mean blood pressure from 175/115 mm Hg to 151/96 mm Hg (p<0.001). Heart rate and forearm blood flow rose, whereas the forearm vascular resistance showed a significant decrease. Side effects of a sensation of heat and reddening of face were noted in some patients. It is suggested that nifedipine may be useful both in the acute and chronic treatment of arterial hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aoki, K., Yoshida, T., Kato, S., Tazumi, K., Sato, I., Takikawa, K., Hotta, K.: Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients. Jap. Heart J.17, 479–484 (1976)
Atterhög, J.-H., Ekelund, L.-G., Melin, A.-L.: Effect of nifedipine on exercise tolerance in patients with angina pectoris. Europ. J. clin. Pharmacol.8, 125–130 (1975)
Chrysant, S. G., Dunn, F. G., de Carvalho, J. G. R., Adamopoulos, P. N., Frohlich, E. D.: Action of nitroglycerin and amyl nitrite in labile and essential hypertension. Arch. int. Med.137, 1702–1705 (1977)
Collier, J. G., Lorge, R. E., Robinson, B. F.: Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprussid on forearm arteries and dorsal hand veins of man. Br. J. clin. Pharmacol.5, 35–44 (1978)
Fleckenstein, A., Tritthart, H., Döring, H. J., Byon, K. Y.: BAY a 1040 — ein hochaktiver Ca++-antagonistischer Inhibitor der elektromechanischen Koppelungsprozesse im Warmblütermyokard. Arzneim.-Forsch.22, 22–23 (1972)
Gribbin, B., Pickering, T. G., Sleight, P., Peto, R.: Effect of age and high blood pressure on baroreflex sensitivity in man. Circ. Res.29, 424–431 (1971)
Grün, G., Fleckenstein, A.: Die elektromechanische Entkoppelung der glatten Gefäßmuskulatur als Grundprinzip der Coronardilatation durch 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäure-dimethylester (BAY a 1040, Nifedipine). Arzneim.-Forsch.22, 334–344 (1972)
Guazzi, M., Olivari, M. T., Polese, A., Fiorentini, C., Magrini, F., Moruzzi, P.: Nifedipine, a new antihypertensive with rapid action. Clin. Pharmacol. Therap.22, 528–532 (1977)
Jacobsen, P., Lederballe Pedersen, O., Mikkelsen, E.: Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection. J. Chromatogr. (In press) (1978)
Klütsch, K., Schmidt, P., Grosswendt, J.: Der Einfluß von BAY a 1040 auf die Nierenfunktion des Hypertonikers. Arzneim.-Forsch.22, 377–380 (1972)
Koch-Weser, J.: Vasodilator drugs in the treatment of hypertension. Arch. int. Med.133, 1017–1027 (1974)
Laaser, U., Meurer, K. A., Kaufmann, W.: Zur klinischen Bewertung der Kombinationsbehandlung von Nifedipin mit verschiedenen Antihypertensiva. Arzneim.-Forsch.27, 676–681 (1977)
Lederballe Pedersen, O.: Does verapamil have a clinically significant antihypertensive effect? Europ. J. clin. Pharmacol.13, 21–24 (1978).
Lederballe Pedersen, O., Mikkelsen, E., Andersson, K.-E.: Effects of extracellular calcium on potassium and noradrenaline induced contractions in the aorta of spontaneously hypertensive rats — Increased sensitivity to nifedipine. Acta pharmacol. toxicol.43, 137–144 (1978)
Mikkelsen, E., Andersson, K.-E., Lederballe Pedersen, O.: The effect of nifedipine on isolated human peripheral vessels. Acta pharmacol. toxicol. (In press) (1978a)
Mikkelsen, E., Andersson, K.-E., Lederballe Pedersen, O.: Verapamil and nifedipine inhibition of contractions induced by potassium and noradrenaline in human mesenterial arteries and veins. Acta Pharmacol. toxicol. (In press) (1978b)
Mostbeck, A., Partsch, H., Peschl, L.: Investigations on peripheral blood distribution. 3rd International Adalat® Symposium, p. 91–97. Amsterdam: Excerpta Medica 1976
Murakami, M., Murakami, E., Takekoshi, N., Tsuchiya, M., Kin, T., Onoe, T., Takeuchi, N., Funatsu, T., Hara, S., Ishise, S., Mifune, J., Maeda, M.: Antihypertensive effect of 4(-2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, BAY a 1040), a new coronary dilator. Jap. Heart J.13, 128–135 (1972)
Raschack, M.: Differences in the cardiac actions of the calcium antagonists verapamil and nifedipine. Arzneim.-Forsch.26, 1330–1333 (1976)
Rämsch, K. D.: Nifedipine: Fluoreszenzspektroskopische Nachweismethode der unveränderten Substanz im Blutplasma nach Gabe therapeutischer Dosen. (To be published)
Tarazi, R. C., Dustan, H. P., Bravo, E. L., Niarchos, A. P.: Vasodilating drugs: contrasting haemodynamic effects. Clin. Sci. mol. Med.51, 575s-578s (1976)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pedersen, O.L., Mikkelsen, E. Acute and chronic effects of nifedipine in arterial hypertension. Eur J Clin Pharmacol 14, 375–381 (1978). https://doi.org/10.1007/BF00716377
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00716377